

# Glaucoma - Acute

From HumanResearchWiki

## Contents

- 1 Introduction
- 2 Clinical Priority and Clinical Priority Rationale by Design Reference Mission
- 3 Initial Treatment Steps During Space Flight
- 4 Capabilities Needed for Diagnosis
- 5 Capabilities Needed for Treatment
- 6 Associated Gap Reports
- 7 Other Pertinent Documents
- 8 List of Acronyms
- 9 References
- 10 Last Update

## Introduction

Acute angle-closure glaucoma is due to an obstructed anterior chamber angle in the eye. Presenting symptoms are severe ocular pain, redness, decreased vision, colored halos around lights, nausea and vomiting, along with elevated intra-ocular pressure. While it is relatively rare and not anticipated in healthy well-screened crewmembers, if it did occur its impact would be potentially significant. Initial treatment of acute glaucoma is directed toward increasing aqueous outflow and decreasing fluid production. Definitive treatment is surgical with procedures such as iridotomy.<sup>[1]</sup>

## Clinical Priority and Clinical Priority Rationale by Design Reference Mission

*One of the inherent properties of space flight is a limitation in available mass, power, and volume within the space craft. These limitations mandate prioritization of what medical equipment and consumables are manifested for the flight, and which medical conditions would be addressed. Therefore, clinical priorities have been assigned to describe which medical conditions will be allocated resources for diagnosis and treatment. “Shall” conditions are those for which diagnostic and treatment capability must be provided, due to a high likelihood of their occurrence and severe consequence if the condition were to occur and no treatment was available. “Should” conditions are those for which diagnostic and treatment capability should be provided if mass/power/volume limitations allow. Conditions were designated as “Not Addressed” if no specific diagnostic and/or treatment capability are expected to be manifested, either due to a very low likelihood of occurrence or other limitations (for example, in medical training, hardware, or consumables) that would preclude treatment. Design Reference Missions (DRMs) are proposed future missions designated by a set of assumptions that encompass parameters such as destination, length of mission, number of crewmembers, number of Extravehicular Activities (EVAs), and anticipated level of care. The clinical priorities for all medical conditions on the Exploration Medical Condition List (EMCL) can be found here ([https://humanresearchwiki.jsc.nasa.gov/index.php?title=Category:All\\_DRM](https://humanresearchwiki.jsc.nasa.gov/index.php?title=Category:All_DRM)). The EMCL document may be accessed here ([https://humanresearchwiki.jsc.nasa.gov/images/6/62/EMCL\\_RevC\\_2013.pdf](https://humanresearchwiki.jsc.nasa.gov/images/6/62/EMCL_RevC_2013.pdf)).*

Design Reference Mission	Clinical Priority	Clinical Priority Rationale
<p>Lunar sortie mission</p> <p>Assumptions:</p> <ul style="list-style-type: none"> <li>▪ 4 crewmembers (3 males, 1 female)</li> <li>▪ 14 days total</li> <li>▪ 4 EVAs/ crewmember</li> <li>▪ <u>Level of Care 3</u></li> </ul>	Not Addressed	The likelihood of glaucoma developing during a lunar sortie mission in the highly pre-screened astronaut cohort is very low, and therefore specific diagnostic or treatment capability will not be manifested for this medical condition.
<p>Lunar outpost mission</p> <p>Assumptions:</p> <ul style="list-style-type: none"> <li>▪ 4 crewmembers (3 males, 1 female)</li> <li>▪ 180 days total</li> <li>▪ 90 EVAs/ crewmember</li> <li>▪ <u>Level of Care 4</u></li> </ul>	Not Addressed	The likelihood of glaucoma developing during a lunar outpost mission in the highly pre-screened astronaut cohort is very low, and therefore specific diagnostic or treatment capability is not required.
<p>Near-Earth Asteroid (NEA) mission</p> <p>Assumptions:</p> <ul style="list-style-type: none"> <li>▪ 3 crewmembers (2 males, 1 female)</li> <li>▪ 395 days total</li> <li>▪ 30 EVAs/ crewmember</li> <li>▪ <u>Level of Care 5</u></li> </ul>	Not Addressed	The likelihood of glaucoma developing during a NEA mission in the highly pre-screened astronaut cohort is very low, and therefore specific diagnostic or treatment capability will not be manifested for this medical condition.

## Initial Treatment Steps During Space Flight

*A link is provided to a prior version of the International Space Station (ISS) Medical Checklist, which outlines the initial diagnostic and treatment steps recommended during space flight for various conditions which may be encountered onboard the ISS. Further diagnostic and treatment procedures beyond the initial steps outlined in the Medical Checklist are then recommended by the ground-based Flight Surgeon, depending on the clinical scenario. Please note that this version does not represent current diagnostic or treatment capabilities available on the ISS. While more recent versions of this document are not accessible to the general public, the provided version of the checklist can still provide a general sense of how medical conditions are handled in the space flight environment. Medical Checklists will be developed for exploration missions at a later point in time.*

Please note this file is over 20 megabytes (MB) in size, and may take a few minutes to fully download.

ISS Medical Checklist ([http://www.nasa.gov/centers/johnson/pdf/163533main\\_ISS\\_Med\\_CL.pdf](http://www.nasa.gov/centers/johnson/pdf/163533main_ISS_Med_CL.pdf))

## Capabilities Needed for Diagnosis

*The following is a hypothetical list of capabilities that would be helpful in diagnosis. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.*

- Intraocular Pressure (IOP) measurement device (such as Tono-Pen)
- Anesthetic ophthalmic solution
- Bandaging
- Cardiac [Electrocardiograph (ECG)] monitor - in acute angle closure glaucoma bradycardia may occur secondary to vagal stimulation
- Visual acuity charts
- Ophthalmoscope

## Capabilities Needed for Treatment

*The following is a hypothetical list of capabilities that would be helpful in treatment. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.*

- Acetazolamide (Diamox, oral)
- Mannitol (oral)
- Ophthalmic steroid solution
- Ophthalmic beta-blocker solution
- Pilocarpine
- Analgesics (non narcotic, oral)
- Prostaglandin analogues

## Associated Gap Reports

*The NASA Human Research Program (HRP) identifies gaps in knowledge about the health risks associated with human space travel and the ability to mitigate such risks. The overall objective is to identify gaps critical to human space missions and close them through research and development. The gap reports that are applicable to this medical condition are listed below. A link to all of the HRP gaps can be found here (<http://humanresearchroadmap.nasa.gov/Gaps/>).*

- 1.01 - We do not know which emerging technologies are suitable for preflight medical screening for exploration missions.
- 2.01 - We do not know the quantified health and mission outcomes due to medical events during exploration missions.
- 2.02 - We do not know how the inclusion of a physician crew medical officer quantitatively impacts clinical outcomes during exploration missions.
- 3.01 - We do not know the optimal training methods for in-flight medical conditions identified on the Exploration Medical Condition List taking into account the crew medical officer's clinical background. (Closed)
- 3.03 - We do not know which emerging technologies are suitable for in-flight screening, diagnosis, and treatment during exploration missions.
- 4.01 - We do not have the capability to provide a guided medical procedure system that integrates with the medical system during exploration missions.
- 4.14 - We do not have the capability to track medical inventory in a manner that integrates securely with the medical system during exploration missions.
- 4.15 - Lack of medication usage tracking system that includes automatic time stamping and crew identification
- 4.17 - We do not have the capability to package medications to preserve stability and shelf-life during exploration missions.
- 4.24 - Lack of knowledge regarding the treatment of conditions on the Space Medicine Exploration Medical Condition List in remote, resource poor environments (Closed)
- 5.01 - We do not have the capability to comprehensively manage medical data during exploration missions.

## Other Pertinent Documents

### List of Acronyms

<b>D</b>	
<a href="#">DRM</a>	Design Reference Mission
<b>E</b>	
<a href="#">ECG</a>	Electrocardiograph
<a href="#">EMCL</a>	Exploration Medical Condition List
<a href="#">EVA</a>	Extravehicular Activity
<b>H</b>	
<a href="#">HRP</a>	Human Research Project
<b>I</b>	
<a href="#">IOP</a>	Intraocular Pressure
<a href="#">ISS</a>	International Space Station
<a href="#">IV</a>	Intravenous
<b>M</b>	
<a href="#">MB</a>	Megabyte
<b>N</b>	
<a href="#">NASA</a>	National Aeronautics and Space Administration
<a href="#">NEA</a>	Near Earth Asteroid

## References

1. Merck Manual. Angle Closure Glaucoma. Porter RS, editor. 2011. Whitehouse Station, N.J, Merck Sharp & Dohme Corp. p 602.

## Last Update

This topic was last updated on 8/12/2014 (Version 2).

Retrieved from "[https://humanresearchwiki.jsc.nasa.gov/index.php?title=Glaucoma\\_-\\_Acute&oldid=5657](https://humanresearchwiki.jsc.nasa.gov/index.php?title=Glaucoma_-_Acute&oldid=5657)"

Category: Medical Conditions

---

- This page was last modified on 12 August 2014, at 15:30.